Assessing the cost‐effectiveness of sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real‐world evidence-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Assessing the cost‐effectiveness of sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real‐world evidence

Published:2020-09-02 Issue:12 Volume:22 Page:2364-2374
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

McEwan Phil¹^ORCID,Bennett Hayley¹,Khunti Kamlesh²,Wilding John³^ORCID,Edmonds Christopher⁴,Thuresson Marcus⁵,Wittbrodt Eric⁴^ORCID,Fenici Peter⁶,Kosiborod Mikhail⁷⁸^ORCID

Affiliation:

1. Health Economics & Outcomes Research Ltd Cardiff UK

2. Diabetes Research Centre University of Leicester, Leicester General Hospital Leicester UK

3. Clinical Sciences Centre University Hospital Aintree Liverpool UK

4. AstraZeneca Gaithersburg Maryland USA

5. Statisticon AB Uppsala Sweden

6. AstraZeneca Cambridge UK

7. Saint Luke's Mid America Heart Institute and University of Missouri‐Kansas City Kansas City Missouri USA

8. The George Institute for Global Health and University of New South Wales Sydney New South Wales Australia

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14162

Reference47 articles.

1. Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit

2. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model

3. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018

4. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023;Diabetes, Obesity and Metabolism;2024-09-02

2. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

3. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile;Expert Opinion on Drug Safety;2024-05-13

4. Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis;Acta Diabetologica;2024-04-18

5. Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?;Expert Review of Clinical Pharmacology;2023-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3